Bafilomycin A1 inhibits the growth and metastatic potential of the BEL-7402 liver cancer and HO-8910 ovarian cancer cell lines and induces alterations in their microRNA expression.

The vacuolar H+-ATPase (V-ATPase) is commonly highly activated in cancer cells and is a potential target of anti-cancer therapy. Bafilomycin A1 is a specific inhibitor of the c subunit of V-ATPase. In the present study, the effects of bafilomycin A1 on the BEL-7402 hepatocellular carcinoma and HO-8910 ovarian cancer cell lines were respectively studied. In addition, the bafilomycin A1-induced alterations in the mRNAs and microRNAs (miRNAs) in the cells were detected using microarray methods. The results demonstrated that the growth of the two cell lines was retarded and the metastatic potential was inhibited by bafilomycin A1. Transmission electron microscopy and assays of capsase-3 and -9 suggested that bafilomycin A1 induced apoptosis. Gene Ontology analysis of the microarrays of mRNA-miRNA integrity showed altered pathways following bafilomycin A1 treatment, including pathways regulating glucose or lipid metabolism, DNA repair or duplication and lysosomes. Quantitative polymerase chain reaction analysis confirmed that miR-923, miR-1246, miR-149*, miR-638 and miR-210 were upregulated and miR-99a, miR-181a-2* and miR-339-5p were downregulated following bafilomycin A1 treatment. The overlapped altered miRs may be effective targets for the two types of solid tumor, and may have potential for application to the treatment of other types of solid tumor.

[1]  R. O'Connor,et al.  HRG-1 enhances cancer cell invasive potential and couples glucose metabolism to cytosolic/extracellular pH gradient regulation by the vacuolar-H+ ATPase , 2014, Oncogene.

[2]  Jiahuai Han,et al.  The lysosomal v-ATPase-Ragulator complex is a common activator for AMPK and mTORC1, acting as a switch between catabolism and anabolism. , 2014, Cell metabolism.

[3]  J. Rubinstein,et al.  Eukaryotic V-ATPase: novel structural findings and functional insights. , 2014, Biochimica et biophysica acta.

[4]  P. Campochiaro,et al.  Lysosomal-mediated waste clearance in retinal pigment epithelial cells is regulated by CRYBA1/βA3/A1-crystallin via V-ATPase-MTORC1 signaling , 2014, Autophagy.

[5]  K. Webster,et al.  Inhibition of the vacuolar ATPase induces Bnip3-dependent death of cancer cells and a reduction in tumor burden and metastasis , 2013, Oncotarget.

[6]  Jaleh Barar,et al.  Dysregulated pH in Tumor Microenvironment Checkmates Cancer Therapy. , 2013, BioImpacts : BI.

[7]  Dennis Brown,et al.  Regulation of luminal acidification by the V-ATPase. , 2013, Physiology.

[8]  Xiaofei Li,et al.  The expression of V-ATPase is associated with drug resistance and pathology of non-small-cell lung cancer , 2013, Diagnostic Pathology.

[9]  W. Westbroek,et al.  Vacuolar H+ ATPase expression and activity is required for Rab27B‐dependent invasive growth and metastasis of breast cancer , 2013, International journal of cancer.

[10]  S. Avnet,et al.  V-ATPase is a candidate therapeutic target for Ewing sarcoma. , 2013, Biochimica et biophysica acta.

[11]  Cory M. Robinson,et al.  Interleukin-27 inhibits phagosomal acidification by blocking vacuolar ATPases. , 2013, Cytokine.

[12]  Y. Wada,et al.  Vacuolar-type proton pump ATPases: acidification and pathological relationships. , 2013, Histology and histopathology.

[13]  C. Plass,et al.  Genome-wide epigenetic regulation of miRNAs in cancer. , 2013, Cancer research.

[14]  T. Taniguchi,et al.  MicroRNAs and DNA damage response , 2013, Cell cycle.

[15]  A. Vollmar,et al.  Mode of Cell Death Induction by Pharmacological Vacuolar H+-ATPase (V-ATPase) Inhibition* , 2012, The Journal of Biological Chemistry.

[16]  Xiaoyan Li,et al.  V-ATPase promotes transforming growth factor-β-induced epithelial-mesenchymal transition of rat proximal tubular epithelial cells. , 2012, American journal of physiology. Renal physiology.

[17]  A. Serrano,et al.  Intracellular proton pumps as targets in chemotherapy: V-ATPases and cancer. , 2012, Current pharmaceutical design.

[18]  S. Sennoune,et al.  Vacuolar H(+)-ATPase signaling pathway in cancer. , 2012, Current protein & peptide science.

[19]  C. Chung,et al.  Enhanced Lysosomal Activity Is Involved in Bax Inhibitor-1-induced Regulation of the Endoplasmic Reticulum (ER) Stress Response and Cell Death against ER Stress , 2011, The Journal of Biological Chemistry.

[20]  C. Mader,et al.  The vacuolar-ATPase (V-ATPase) modulates matrix metalloproteinase (MMP) isoforms in human pancreatic cancer , 2010, Laboratory Investigation.

[21]  Reinhard Dechant,et al.  Cytosolic pH is a second messenger for glucose and regulates the PKA pathway through V‐ATPase , 2010, The EMBO journal.

[22]  T. Schüpbach,et al.  The vacuolar proton pump, V-ATPase, is required for notch signaling and endosomal trafficking in Drosophila. , 2009, Developmental cell.

[23]  M. Akita,et al.  The proton pump inhibitor inhibits cell growth and induces apoptosis in human hepatoblastoma , 2008, Pediatric Surgery International.

[24]  M. Futai,et al.  The V-type H+-ATPase in vesicular trafficking: targeting, regulation and function , 2008, Current Opinion in Cell Biology.

[25]  F. Lozupone,et al.  Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. , 2004, Journal of the National Cancer Institute.

[26]  Shigenori Tamaki,et al.  Vacuolar H+-ATPase inhibitor induces apoptosis via lysosomal dysfunction in the human gastric cancer cell line MKN-1. , 2003, Journal of biochemistry.

[27]  T. Nishi,et al.  The vacuolar (H+)-ATPases — nature's most versatile proton pumps , 2002, Nature Reviews Molecular Cell Biology.

[28]  T. Terada,et al.  Bafilomycin A1 induces apoptosis in the human pancreatic cancer cell line Capan‐1 , 1998, The Journal of pathology.